Patient Alert Card

Prescriber Guide

Apixaban tablets Alert Card - Adult

Apixaban Alert Card - Paediatric population

Apixaban Prescriber Guide

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material before prescribing Apixaban as it contains important safety information on the important risks of bleeding, and medication errors during treatment with Apixaban and their appropriate management.

Patient Alert Card

Prescriber guide

Apixaban-Patient Alert Card

Apixaban-Prescriber Guide

Patient alert card

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

This risk minimisation material is for Apixaban Krka tablets for all indications. Please ensure that you are familiar with this material before prescribing Apixaban Krka as it contains important safety information on the potential risk of bleeding during treatment with Apixaban and provides guidance on how to manage that risk. If you would like to obtain hard copies of the Apixaban Krka 2.5mg & 5mg Prescriber Guide and/or Patient Alert Card and/or SPCs, please contact Krka UK Limited (Email: [email protected], phone: +44 (0) 207 164 6156). Risk minimisation materials can only be delivered to UK registered healthcare premises.

Patient Alert Card

Apixaban Prescriber Guide

Apixaban 2.5mg & 5mg Prescribers Guide. This educational material is provided to further minimize the risk of bleeding that is associated with the use of apixaban and to guide healthcare professionals in managing that risk.

HCP prescriber guide for Apixaban

Patient alert card for Apixaban

Prescriber guide for Apixaban film coated tablets (version 2)

Patient alert card for Apixaban 2.5mg FCT

Patient Alert card for Apixaban 5mg film coated tablets, pack size 56

Patients prescribed with Apixaban 2.5 mg and 5 mg film-coated tablets from Marketing Authorisation Holder, Silicon Pharma Limited will receive a Patient Alert Card in the medication pack along with the package leaflet. Please ensure you have read and understood the information in the card because it contains important safety information including the importance of taking Apixaban tablets regularly as instructed by your treating Doctor, the main signs and symptoms of bleeding, and when to seek medical attention. Please carry the Patient Alert Card with you at all times and show it to every healthcare professional including pharmacists. Patient Alert Card is approved by MHRA in 11/2025. This is for UK Only additional risk minimisation materials.

This additional risk minimisation material is for Apixaban 2.5 mg and 5 mg film coated tablet from Marketing Authorisation Holder, Silicon Pharma Limited. Please ensure that you are familiar with this material before prescribing Apixaban Tablets as it contains important safety information on the potential risk of bleeding during treatment and provides guidance on how to manage that risk. Prescriber Guide is approved by MHRA in 11/2025. This is for UK Only additional risk minimisation material.

This risk minimisation material is a condition of the marketing authorisation. Please ensure that you are familiar with this material before prescribing Eliquis as it contains important safety information on the important risks of bleeding, and medication errors during treatment with apixaban and their appropriate management.